

RNS Number : 5872M

Genflow Biosciences PLC

12 June 2025

12 June 2025

Genflow Biosciences Plc

Results of Annual General Meeting

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Votes withheld
1. To receive and consider the Annual Report and Accounts for the year ended 31 December 2024 together with the Directors' Report and Auditors' Report thereon.	152,365,311	99.5%	312	0.0%	152,365,623	753,187
2. To approve the directors'	152,069,752	99.3%	270,744	0.2%	152,340,496	778,314

remuneration report for the financial period ended 31 December 2024 set out in the audited accounts for the financial period ended 31 December 2024.						
3. To re-appoint PKF Littlejohn LLP as auditors of the Company and to authorise the Directors of the Company to fix their remuneration.	151,451,787	98.9%	121,889	0.1%	151,573,676	1,545,134
4. To re-elect Tamara Joseph as a Director of the Company.	151,449,590	98.9%	206,583	0.1%	151,656,173	1,462,637
5. To re-elect Dr Guy-Charles Fanneau de La Horie as a Director of the Company.	151,448,295	98.9%	207,469	0.1%	151,655,764	1,463,046
6. To re-elect Dr Eric Leire as a Director of the Company.	152,668,756	99.7%	192,686	0.1%	152,861,442	257,368

7. To re-elect Dr Yassine Bendiabdallah as a Director of the Company.	151,442,263	98.9%	213,734	0.1%	151,655,997	1,462,813
8. To re-elect Dr Peter King Lewis as a Director of the Company.	152,636,489	99.7%	192,843	0.1%	152,829,332	289,478
9. To authorise the Directors to allot shares in the Company.	132,658,404	86.6%	19,655,616	12.8%	152,314,020	804,790
Special Resolution	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Votes withheld
10. To disapply statutory pre-emption rights.	132,698,727	86.7%	18,861,048	12.3%	151,559,775	1,559,035

Contacts

Harbor Access

Genflow Biosciences

Dr Eric Leire, CEO

+32-477-495-881

Jonathan Paterson, Investor Relations

+1 475 477 9401

Jonathan.Paterson@Harbor-access.com

Corporate Brokers

Capital Plus Partners Ltd

Jon Critchley, +44 0203 821 6168

About Genflow

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.

Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.